Novo Nordisk invests DKK2.1bn in new insulin filling facility in Denmark
The facility will produce medicines for the treatment of diabetes and obesity and 450 new jobs will be created
Novo Nordisk is investing DKK2.1bn (approximately US$303m) in a new 10,300m2 facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity.
The company held a groundbreaking ceremony on marking the start of construction work, at the Hillerød site on 4 November, which was attended by the mayor of Hillerød, Dorte Meldgaard.
The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people.
Incorporating the latest insulin production technology, the new filling facility will ensure production capacity for existing and future products within diabetes.
'The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark,' said Henrik Wulff, Executive Vice President and Head of Product Supply at Novo Nordisk.
'This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød.'
